- Home
- XFOR vs RPTX Comparison
XFOR vs RPTX Comparison
Compare XFOR & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- RPTX
- Stock Information
- Founded
- XFOR 2014
- RPTX 2016
- Country
- XFOR United States
- RPTX Canada
- Employees
- XFOR N/A
- RPTX N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- RPTX Health Care
- Exchange
- XFOR Nasdaq
- RPTX Nasdaq
- Market Cap
- XFOR 84.3M
- RPTX 78.2M
- IPO Year
- XFOR N/A
- RPTX 2020
- Fundamental
- Price
- XFOR $3.80
- RPTX $1.79
- Analyst Decision
- XFOR Strong Buy
- RPTX Strong Buy
- Analyst Count
- XFOR 3
- RPTX 3
- Target Price
- XFOR $34.17
- RPTX $3.50
- AVG Volume (30 Days)
- XFOR 1.5M
- RPTX 197.0K
- Earning Date
- XFOR 11-12-2025
- RPTX 11-07-2025
- Dividend Yield
- XFOR N/A
- RPTX N/A
- EPS Growth
- XFOR N/A
- RPTX N/A
- EPS
- XFOR N/A
- RPTX N/A
- Revenue
- XFOR $32,774,000.00
- RPTX $250,000.00
- Revenue This Year
- XFOR $1,307.51
- RPTX N/A
- Revenue Next Year
- XFOR N/A
- RPTX N/A
- P/E Ratio
- XFOR N/A
- RPTX N/A
- Revenue Growth
- XFOR 5721.31
- RPTX N/A
- 52 Week Low
- XFOR $1.35
- RPTX $0.89
- 52 Week High
- XFOR $26.83
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- XFOR 62.57
- RPTX 46.12
- Support Level
- XFOR $2.96
- RPTX $1.76
- Resistance Level
- XFOR $4.54
- RPTX $1.97
- Average True Range (ATR)
- XFOR 0.26
- RPTX 0.08
- MACD
- XFOR 0.08
- RPTX -0.01
- Stochastic Oscillator
- XFOR 57.47
- RPTX 23.40
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.